Haemonetics (HAE) EVP Roy Galvin granted RSUs as 879 shares withheld for taxes

Rhea-AI Filing Summary

Haemonetics EVP and Chief Commercial Officer Roy Galvin reported routine equity compensation activity involving restricted stock units (RSUs) and related tax withholding. He received a grant of 27,535 shares of common stock in the form of RSUs under the company’s long-term incentive plan. These RSUs vest over three years, with 40% vesting on each of the first two anniversaries of the grant date and 20% on the third anniversary. On the same date, 879 shares valued at $56.29 per share were withheld to cover tax obligations tied to vesting RSUs, rather than sold on the open market. Following these transactions, he directly holds 12,347 shares of common stock, a figure that includes unvested RSUs previously reported and 415 shares acquired through the Haemonetics Corporation 2007 Employee Stock Purchase Plan.

Insights

Equity compensation analyst

Routine RSU grant and tax withholding with no open-market trading.

The filing shows Roy Galvin, EVP and Chief Commercial Officer of Haemonetics, receiving an equity award of 27,535 RSUs that convert to common stock as they vest. The three-year 40/40/20 vesting schedule is typical for executive long-term incentives.

Separately, 879 shares at $56.29 per share were withheld to satisfy tax obligations on vesting RSUs, not sold in the market. After these events, Galvin directly holds 12,347 shares, including previously reported unvested RSUs and 415 shares from the employee stock purchase plan. Overall, this is standard compensation-related activity with limited signaling value for investors.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Galvin Roy

Role EVP, Chief Commercial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	879	$56.29	$49K
Grant/Award	Common Stock	27,535	$0.00	--

Holdings After Transaction: Common Stock — 12,347 shares (Direct, null)

Footnotes (1)

1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. This number includes unvested RSUs previously reported as well as 415 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Key Figures

RSU grant: 27,535 shares Tax withholding shares: 879 shares Tax withholding price: $56.29 per share +3 more

6 metrics

RSU grant 27,535 shares Common stock RSUs granted to Roy Galvin on May 15, 2026

Tax withholding shares 879 shares Shares withheld to cover tax obligations at $56.29 per share

Tax withholding price $56.29 per share Value applied to 879 shares withheld for RSU-related taxes

Post-transaction holdings 12,347 shares Direct common stock holdings after transactions, including unvested RSUs and ESPP shares

ESPP shares 415 shares Shares acquired under the 2007 Employee Stock Purchase Plan on April 30, 2026

Vesting schedule 40% / 40% / 20% Annual vesting pattern over three years for the RSU award

Key Terms

restricted stock units ("RSUs"), Employee Stock Purchase Plan, Long-Term Incentive Compensation Plan, tax obligations, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Employee Stock Purchase Plan financial

"415 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Long-Term Incentive Compensation Plan financial

"RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan"

tax obligations financial

"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units"

contingent right financial

"Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Galvin Roy

(Last) (First) (Middle)

125 SUMMER STREET

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		F		879(1)	D	$56.29	12,347(2)	D
Common Stock	05/15/2026		A		27,535(3)	A	(4)	39,882(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

2. This number includes unvested RSUs previously reported as well as 415 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.

3. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

4. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

	/s/ Thomas V. Powers, attorney-in-fact for Mr. Galvin	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)